期刊
EUROPEAN HEART JOURNAL
卷 42, 期 22, 页码 2170-2185出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehaa1050
关键词
Chronic kidney disease; Cardiovascular disease; Lipoproteins; Low-density lipoprotein; High-density lipoprotein; Triglycerides; Atherosclerosis; Lipid-lowering therapy
资金
- Deutsche Forschungsgemeinschaft ( DFG SFB/TRR 219) [322900939]
- European Uremic Toxin (EUTOX)
- Swiss National Science Foundation
- Swiss Heart Foundation
Chronic kidney disease (CKD) is linked to a higher risk of cardiovascular diseases, with specific lipoprotein patterns seen in CKD patients. These lipoprotein modifications affect their structure and function, contributing to the development of CKD-related cardiovascular diseases.
Chronic kidney disease (CKD) is associated with high cardiovascular risk. CKD patients exhibit a specific lipoprotein pattern termed 'uraemic dyslipidaemia', which is characterized by rather normal low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, and high triglyceride plasma levels. All three lipoprotein classes are involved in the pathogenesis of CKD-associated cardiovascular diseases (CVDs). Uraemia leads to several modifications of the structure of lipoproteins such as changes of the proteome and the lipidome, post-translational protein modifications (e.g. carbamylation) and accumulation of small-molecular substances within the lipoprotein moieties, which affect their functionality. Lipoproteins from CKD patients interfere with lipid transport and promote inflammation, oxidative stress, endothelial dysfunction as well as other features of atherogenesis, thus contributing to the development of CKD-associated CVD. While, lipid-modifying therapies play an important role in the management of CKD patients, their efficacy is modulated by kidney function. Novel therapeutic agents to prevent the adverse remodelling of lipoproteins in CKD and to improve their functional properties are highly desirable and partially under development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据